SCHEMBL683655

SCHEMBL683655

Cn1c(=O)c2c(ncn2CN2CCN(c3ccccc3)CC2)n(C)c1=O

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.77
HTR6 P50406 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.70
SMN1; SMN2 Q16637 2/20 0.59
RXFP1 Q9HBX9 2/20 0.59
ADORA2B P29275 1/20 0.59
ALDH1A1 P00352 4/20 0.58
HTR1A P08908 1/20 0.57
HTR2A P28223 1/20 0.57
RAB9A P51151 1/20 0.56
TSHR P16473 3/20 0.56
MAPK1 P28482 2/20 0.56
LMNA P02545 2/20 0.53
HTT P42858 2/20 0.53
HSD17B10 Q99714 1/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810048 0.91 HTR7 (0.84) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL682813 0.90 HTR7 (0.62) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL682817 0.89 LMNA (0.62) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL684362 0.89 RAB9A (0.71) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL683995 0.88 MAPK1 (0.72) HTR7HTR6L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL683656 0.88 HTR7 (0.61) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL683604 0.87 RXFP1 (0.62) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL683994 0.86 RXFP1 (0.63) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL684028 0.86 HTR7 (0.58) HTR7HTR6L3MBTL1SMN1; SMN2RXFP1
SCHEMBL684041 0.86 HTR7 (0.58) HTR7HTR6L3MBTL1RXFP1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150306107-A1 SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia JANSFAT BIOTECHNOLOGY CO., LTD. (TW) 2015-10-29 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150306107-A1 SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia SAAL1, HMOX1, HIF1AN HTR7 3988/4885HTR6 1856/4885L3MBTL1 1613/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR7 1398/4885HTR6 683/4885L3MBTL1 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.